- Potential benefitIncreases statutory clarity and predictability about what is eligible for patent protection.
- Potential benefitLikely expands the range of inventions eligible for patents, potentially increasing patent grants.
- Potential benefitCould boost private investment and commercialization incentives in tech and life sciences.
Patent Eligibility Restoration Act of 2025
Read twice and referred to the Committee on the Judiciary.
The bill, the Patent Eligibility Restoration Act of 2025, revises 35 U.S.C. §101 to broadly restore patent eligibility for any useful process, machine, manufacture, or composition of matter, subject to a short list of explicit exclusions. It eliminates judicial exceptions (like abstract ideas and laws of nature) and requires eligibility be assessed by considering the claim as a whole and without regard to novelty, obviousness, or specification requirements.
Liberals emphasize public-health and research access concerns
Relative to its intended legislative type, this bill is a clearly articulated statutory overhaul of patent subject-matter eligibility that supplies concrete amendments to 35 U.S.C. 100 and 101 and addresses many common borderline categories, but it leaves several operational and interpretive details to be resolved outside the text.
The bill, the Patent Eligibility Restoration Act of 2025, revises 35 U.S.C. §101 to broadly restore patent eligibility for any useful process, machine, manufacture, or composition of matter, subject to a short list of explicit exclusions.
It eliminates judicial exceptions (like abstract ideas and laws of nature) and requires eligibility be assessed by considering the claim as a whole and without regard to novelty, obviousness, or specification requirements.
Express exclusions include standalone mathematical formulas, solely mental processes, unmodified human genes and natural materials, and processes that are substantially economic, financial, business, social, cultural, or artistic unless they cannot practically be performed without a machine.
Substantial industry backing can help, but contentious impact on biotech, diagnostics, software, and litigation incentives reduces chances absent significant compromise.
Relative to its intended legislative type, this bill is a clearly articulated statutory overhaul of patent subject-matter eligibility that supplies concrete amendments to 35 U.S.C. 100 and 101 and addresses many common borderline categories, but it leaves several operational and interpretive details to be resolved outside the text.
Liberals emphasize public-health and research access concerns
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenMay enable broader software and business-method patents, increasing risk of monopolistic or exclusionary claims.
- Potential burdenRestricting eligibility challenges could shift disputes to other doctrines and raise litigation volume and costs.
- Potential burdenProhibiting consideration of novelty or obviousness during eligibility determinations may allow lower-quality patents t…
Why the argument around this bill splits.
Liberals emphasize public-health and research access concerns
Generally skeptical.
The persona values clarity for inventors but worries the bill will expand patent rights in ways that can hinder access to medicine, research, and digital rights.
They would welcome clearer law but fear negative public-interest consequences without strong safeguards.
Cautiously optimistic but pragmatic.
The persona appreciates legal clarity and reduced judicial uncertainty, while wanting measures to limit low-quality patents and excessive litigation.
Supports improvements if paired with implementation safeguards and PTO guidance.
Generally supportive.
The persona views the bill as correcting judicial overreach, restoring property rights in inventions, and promoting innovation and economic growth.
Concerns focus primarily on limiting frivolous litigation and abusive assertion, not on eligibility rollback.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantial industry backing can help, but contentious impact on biotech, diagnostics, software, and litigation incentives reduces chances absent significant compromise.
- Absent official cost/impact estimate on PTO workload and courts
- How major stakeholders (pharma, universities, tech, public-interest groups) will align
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Liberals emphasize public-health and research access concerns
Substantial industry backing can help, but contentious impact on biotech, diagnostics, software, and litigation incentives reduces chances…
Relative to its intended legislative type, this bill is a clearly articulated statutory overhaul of patent subject-matter eligibility that supplies concrete amendments to 35 U.S.C. 100 and 101 and addresses many common…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.